When is Febuxostat Used Instead of Allopurinol for Gout? 

In the UK, allopurinol is almost always the first choice for long-term gout prevention. However, it is not suitable for everyone. For patients who cannot tolerate allopurinol or for whom the medication is not effective, febuxostat provides a powerful and vital alternative. Like allopurinol, febuxostat is a xanthine oxidase inhibitor that lowers uric acid levels in the blood, but it has a different chemical structure and is processed by the body in a distinct way. Understanding when and why a doctor might switch your treatment is an important part of personalising your gout management. 

What We Will Discuss in This Article 

• The primary clinical reasons for switching from allopurinol to febuxostat 

• How febuxostat works for patients with chronic kidney disease 

• Managing allopurinol hypersensitivity and side effects 

• The difference in effectiveness and dosing between the two drugs 

• Important cardiovascular safety considerations for febuxostat 

• When sudden joint pain requires an urgent 999 clinical review 

The Second-Line Role of Febuxostat 

In the UK, clinicians follow a specific pathway for urate-lowering therapy. According to NICE technology appraisal guidance (TA164), febuxostat is recommended as an option for the management of chronic hyperuricaemia in gout only if allopurinol is not tolerated or is contraindicated. 

This means that most patients will start on allopurinol first. If you develop a significant side effect or if your uric acid levels do not reach the required target despite taking the maximum safe dose of allopurinol, your GP or rheumatologist will then consider a switch to febuxostat. 

Reasons for Making the Switch 

1. Allopurinol Intolerance and Sensitivity 

The most common reason for switching is a side effect. While rare, some people develop a skin rash or more severe hypersensitivity to allopurinol. If you experience any allergic reaction, the medication must be stopped immediately. Since febuxostat has a completely different chemical structure, it is often a safe and effective alternative for these patients. 

2. Chronic Kidney Disease (CKD) 

Allopurinol is primarily cleared from the body through the kidneys. In patients with significant kidney impairment, the dose of allopurinol often has to be kept very low to ensure safety, which might prevent the uric acid from reaching its target. Febuxostat is mainly processed by the liver, making it a very useful option for people with moderate to severe kidney issues who need effective urate-lowering without putting extra stress on their renal system. 

3. Failure to Reach Target Urate Levels 

For some individuals, allopurinol simply does not lower the uric acid enough, even at high doses. Febuxostat is often more potent at its standard starting dose. If the treat to target goal (usually below 360 µmol/L) is not being met with allopurinol, febuxostat can provide the extra strength needed to dissolve the crystal deposits in the joints. 

Comparing Allopurinol and Febuxostat 

Feature	Allopurinol	Febuxostat
First-Line Use	Yes, the standard UK starting drug.	No, used as a second-line alternative.
Primary Clearance	Kidneys (Renal).	Liver (Hepatic).
Common Starting Dose	100mg once daily.	80mg once daily.
Potency	Dose-dependent; requires titration.	Generally highly potent at lower doses.
NICE Status	Standard care.	Recommended if allopurinol is unsuitable.

Cardiovascular Safety Considerations 

While febuxostat is highly effective, UK clinicians use it with caution in patients with a history of serious heart disease. Some clinical trials have suggested a potential increase in cardiovascular events for patients taking febuxostat compared to those on allopurinol. 

If you have a history of heart attack, stroke, or unstable angina, your doctor will carefully weigh the benefits of febuxostat against these risks. In many cases, if your heart health is stable and allopurinol is not an option, febuxostat remains a vital tool for preventing the long-term damage caused by gout. 

The Transition Phase 

Just like allopurinol, starting febuxostat can cause a temporary increase in gout flares as the uric acid levels in the blood begin to drop.⁷ This is a sign that the medication is working and that crystals are starting to shift. In the UK, a low dose of an anti-inflammatory, such as colchicine, is usually prescribed for the first six months of febuxostat treatment to “bridge” this transition and keep you comfortable. 

Conclusion 

Febuxostat is the primary alternative to allopurinol in the UK, used when patients experience side effects, have significant kidney disease, or cannot reach their uric acid target with first-line treatment. By providing a different metabolic pathway for lowering urate, it ensures that even patients with complex health needs can achieve long-term freedom from gout flares. If you feel your current treatment is not working or is causing side effects, discussing a switch to febuxostat with your GP is a proactive step in your care. 

If you experience severe, sudden joint pain accompanied by a high temperature, chills, or feeling generally unwell, call 999 or go to A&E immediately, as this may be a sign of a serious infection. 

Authority Snapshot (E-E-A-T Block) 

This article was written by Dr. Stefan Petrov, a UK-trained physician with an MBBS and experience in general medicine, surgery, and emergency care. Dr. Petrov has worked in various NHS settings, helping patients manage complex inflammatory conditions according to NICE and NHS standards. This guide provides an authoritative overview of the clinical use of febuxostat in the UK.